Recent publications on Residual Risk

This timely review has highlighted the potential of therapeutic approaches targeting angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) to reduce triglyceride-rich lipoproteins and related residual cardiovascular risk. Ongoing research has led to new biologicals that suppress the expression or inhibit the function of these two key proteins. These include human monoclonal antibodies or antisense oligonucleotides. This article reviews the mechanisms of action of ANGPTL3 and apoC-III, and why intervening against these targets may offer future promise for reduction in residual cardiovascular risk.